FDA Application
-
NDC Search Results on Active Ingredient: acetaminophen
Click on Active Ingredient to view the label.
Ingredient Name | NDC | Company Name | Application Number or Regulatory Citation | Product Type | Marketing Category |
---|---|---|---|---|---|
ACETAMINOPHEN | 82179-002-04 | Mollec Inc | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
ACETAMINOPHEN | 71444-893-01 | Mom Enterprises, LLC. | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
ACETAMINOPHEN | 71444-793-02 | Mom Enterprises, LLC. | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
ACETAMINOPHEN | 71444-793-01 | Mom Enterprises, LLC. | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
ACETAMINOPHEN; PHENYLEPHRINE HYDROCHLORIDE | 55670-150-13 | Moore Medical LLC | part341 | HUMAN OTC DRUG | OTC monograph final |
ACETAMINOPHEN | 55670-468-13 | Moore Medical LLC | part343 | HUMAN OTC DRUG | OTC monograph not final |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-161-02 | Mutual Pharmaceutical Company, Inc. | ANDA089673 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-159-10 | Mutual Pharmaceutical Company, Inc. | ANDA089671 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-160-01 | Mutual Pharmaceutical Company, Inc. | ANDA089672 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-161-05 | Mutual Pharmaceutical Company, Inc. | ANDA089673 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-160-05 | Mutual Pharmaceutical Company, Inc. | ANDA089672 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-159-05 | Mutual Pharmaceutical Company, Inc. | ANDA089671 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-159-01 | Mutual Pharmaceutical Company, Inc. | ANDA089671 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-161-01 | Mutual Pharmaceutical Company, Inc. | ANDA089673 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-160-10 | Mutual Pharmaceutical Company, Inc. | ANDA089672 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-161-10 | Mutual Pharmaceutical Company, Inc. | ANDA089673 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-159-02 | Mutual Pharmaceutical Company, Inc. | ANDA089671 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; CODEINE PHOSPHATE | 53489-160-02 | Mutual Pharmaceutical Company, Inc. | ANDA089672 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN | 67457-940-10 | Mylan Institutional LLC | ANDA213255 | HUMAN PRESCRIPTION DRUG | ANDA |
ACETAMINOPHEN; PYRILAMINE MALEATE; CAFFEINE | 67751-145-01 | Navajo Manufacturing Company Inc. | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
ACETAMINOPHEN | 67751-167-02 | Navajo Manufacturing Company Inc. | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
ACETAMINOPHEN | 67751-167-03 | Navajo Manufacturing Company Inc. | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE; CHLORPHENIRAMINE MALEATE | 67751-217-02 | Navajo Manufacturing Company Inc. | part341 | HUMAN OTC DRUG | OTC monograph final |
ACETAMINOPHEN | 67751-167-04 | Navajo Manufacturing Company Inc. | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
CAFFEINE; ACETAMINOPHEN; ASPIRIN | 67751-119-02 | Navajo Manufacturing Company Inc. | part343 | HUMAN OTC DRUG | OTC monograph not final |
ACETAMINOPHEN; IBUPROFEN | 67751-211-01 | Navajo Manufacturing Company Inc. | NDA211733 | HUMAN OTC DRUG | NDA |
ACETAMINOPHEN; IBUPROFEN | 67751-211-02 | Navajo Manufacturing Company Inc. | NDA211733 | HUMAN OTC DRUG | NDA |
ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE; CHLORPHENIRAMINE MALEATE | 67751-217-01 | Navajo Manufacturing Company Inc. | part341 | HUMAN OTC DRUG | OTC monograph final |
ACETAMINOPHEN; PYRILAMINE MALEATE; CAFFEINE | 67751-145-02 | Navajo Manufacturing Company Inc. | M013 | HUMAN OTC DRUG | OTC Monograph Drug |
CAFFEINE; ACETAMINOPHEN; ASPIRIN | 67751-119-01 | Navajo Manufacturing Company Inc. | part343 | HUMAN OTC DRUG | OTC monograph not final |
-